What We Do

Advancing Dosimetry-Guided Radiopharmaceutical Therapy (DG-RPT)

What is RPT?

Radiopharmaceutical therapy (RPT) is an attractive alternative to chemotherapy for many cancer patients. RPT works by tagging a radionuclide to a drug-carrier that specifically targets tumor cells. Once the drug locks onto a tumor cell, the radionuclide delivers a toxic dose of radiation. As a much more targeted radionuclide therapy, it spares healthy tissue and can provide better outcomes.

What is Dosimetry-Guided RPT?

Today’s RPT standard of care doesn’t address interpatient variability. Standardized dosing can fail to achieve a cure due to underdosing, or present a risk of induced side effects due to overdosing.

Studies have shown the uptake of the drug in tumors or critical organs can vary as much as five-fold between patients. Dosimetry-guided RPT (DG-RPT) helps tailor treatment plans to fit a patient’s individual drug-interaction (pharmacokinetics). A personalized treatment can potentially lead to longer overall survival, increased tumor response, and higher quality of life.

Effective DG-RPT Treatment Planning

Dose Assessment

The ability to measure the absorbed dose (AD) delivered to each tumor or critical structure following administration of therapeutic activity.*


*510(k) pending. Torch™ is under FDA review and is NOT available for sale or clinical use. 

Treatment Planning

The ability to define an optimum treatment course for a patient based on individual PK information, including the number of therapy cycles and size of administered activity per cycle.*

*Works-in-progress not available for sale.

Adaptive Planning

Because a patient’s drug interaction may change over the course of therapy, it is important to have the ability to adapt the treatment plan in response.*


*Works-in-progress not available for sale.

Dose Assessment

The ability to measure the absorbed dose (AD) delivered to each tumor or critical structure following administration of therapeutic activity.*


*510(k) pending. Torch™ is under FDA review and is NOT available for sale or clinical use. 

Treatment Planning

The ability to define an optimum treatment course for a patient based on individual PK information, including the number of therapy cycles and size of administered activity per cycle.*

*Works-in-progress not available for sale.

Adaptive Planning

Because a patient's drug interaction may change over the course of therapy, it is important to have the ability to adapt the treatment plan in response.*


*Works-in-progress not available for sale.

Torch

GPU-Accelerated RPT Dose Assessment

Torch™ simplifies the otherwise complex task of analyzing a patient’s nuclear medicine scans to develop a personalized assessment, including estimates of patient-specific pharmacokinetics and calculation of dose to the patient’s tumors and critical structures. *

*510(k) pending. Torch™ is under FDA review and is NOT available for sale or clinical use. 

NEWS & WEBINARS

Voximetry will be at Theranostics World Congress, Wiesbaden Germany